Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls – Psychedelic Alpha

Featured content in this Issue:

  • Incannex Shares Topline Results from Phase 2a Study of Psilocybin for Generalised Anxiety Disorder
  • An Uptick in Psilocybin-Related Poison Centre Calls
  • Compass Pushes Back First Phase 3 Readout to Q4
  • GH Research Preparing to Conduct Phase 1 Study of Proprietary Device in Europe if FDA Hold Not Resolved
  • Further Reading & Other Stories

Companies and candidates mentioned in this Bulletin: Incannex Healthcare, PSX-001, MindMed, MM-120, Cybin, CYB004, Compass Pathways, GH Research, GH001, Enveric Biosciences, atai Life Sciences, aNUma.

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Sign-in button

Join Button

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Subscribe

* indicates required